SRPT — Sarepta Therapeutics Inc

Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on NASDAQ. It is led by Douglas S. Ingram Esq., J.D., based in 215 First Street, Cambridge, MA, United States, 02142, with about 1,372 employees. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest reported SRPT revenue for 2025-09-30 was $399.4M. Net income was -$430.6M. Revenue was down 34.6% from 2025-06-30 to 2025-09-30. SRPT currently screens at market cap $2.34B.

Use this SRPT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SRPT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SRPT SEC filings page. Lician reads the product cache first so this HTML stays unique to Sarepta Therapeutics Inc even when a live quote feed is slow.